Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study.

Autor: Rognvaldsson S; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland., Eythorsson E; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland., Thorsteinsdottir S; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.; Rigshospitalet, Copenhagen, Denmark., Vidarsson B; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland., Onundarson PT; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland., Agnarsson BA; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland., Sigurdardottir M; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland., Thorsteinsdóttir I; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland., Olafsson I; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland., Runolfsdottir HL; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland., Helgason D; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland., Emilsdottir AR; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland., Agustsson AS; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland., Bjornsson AH; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland., Kristjansdottir G; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland., Thordardottir AR; Faculty of Medicine, University of Iceland, Reykjavik, Iceland., Indridason OS; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland., Jonsson A; Akureyri Hospital, Akureyri, Iceland., Gislason GK; Faculty of Medicine, University of Iceland, Reykjavik, Iceland., Olafsson A; Faculty of Medicine, University of Iceland, Reykjavik, Iceland., Steingrimsdottir H; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland., Kampanis P; The Binding Site ltd, Birmingham, UK., Hultcrantz M; Memorial Sloan-Kettering Cancer Center, New York City, NY, USA., Durie BGM; Cedar-Sinai Samual Oschin Cancer Center, Los Angeles, CA, USA., Harding S; The Binding Site ltd, Birmingham, UK., Landgren O; Sylvester Cancer Center, University of Miami, Miami, FL, USA., Palsson R; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland., Love TJ; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland., Kristinsson SY; Faculty of Medicine, University of Iceland, Reykjavik, Iceland. sigyngvi@hi.is.; Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland. sigyngvi@hi.is.
Jazyk: angličtina
Zdroj: Blood cancer journal [Blood Cancer J] 2021 Dec 01; Vol. 11 (12), pp. 191. Date of Electronic Publication: 2021 Dec 01.
DOI: 10.1038/s41408-021-00580-7
Abstrakt: Multiple myeloma (MM) patients have increased risk of severe coronavirus disease 2019 (COVID-19) when infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Monoclonal gammopathy of undetermined significance (MGUS), the precursor of MM has been associated with immune dysfunction which may lead to severe COVID-19. No systematic data have been published on COVID-19 in individuals with MGUS. We conducted a large population-based cohort study evaluating the risk of SARS-CoV-2 infection and severe COVID-19 among individuals with MGUS. We included 75,422 Icelanders born before 1976, who had been screened for MGUS in the Iceland Screens Treats or Prevents Multiple Myeloma study (iStopMM). Data on SARS-CoV-2 testing and COVID-19 severity were acquired from the Icelandic COVID-19 Study Group. Using a test-negative study design, we included 32,047 iStopMM participants who had been tested for SARS-CoV-2, of whom 1754 had MGUS. Among these participants, 1100 participants, tested positive, 65 of whom had MGUS. Severe COVID-19 developed in 230 participants, including 16 with MGUS. MGUS was not associated with SARS-CoV-2 infection (Odds ratio (OR): 1.05; 95% confidence interval (CI): 0.81-1.36; p = 0.72) or severe COVID-19 (OR: 0.99; 95%CI: 0.52-1.91; p = 0.99). These findings indicate that MGUS does not affect the susceptibility to SARS-CoV-2 or the severity of COVID-19.
(© 2021. The Author(s).)
Databáze: MEDLINE
Externí odkaz: